Replies to post #188030 on Biotech Values

[DewDiligence]

FDA approves B-I’s Praxbind (f/k/a idarucizumab)—a reversal agent for Pradaxa:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm467300.htm

This may help Pradaxa compete more effectively against FXa inhibitors such as Xarelto and Eliquis.